What We're Reading: Page 142
Industry reads hand-picked by our editors
Aug 16, 2021
-
Associated Press
Former FDA chief on the case for a more independent agency
-
The New York Times
U.S. Preparing Plan to Offer Vaccine Boosters, Perhaps By Fall
-
Endpoints News
Prosecutors secure guilty plea in $110M biotech scam at Vermont ski resort
-
Evaluate Vantage
Travere lines up another shot at speedy sparsentan approval
Aug 13, 2021
-
The New York Times
F.D.A. Approves GHB, a 'Date Rape' Drug, for Rare Sleeping Disorder
-
STAT
Ellis Unger, an outspoken FDA veteran, resigns
-
The Atlantic
Vaccine Analogies Are Failing Us
-
Bloomberg
The Tesla-fication of Moderna Is a Rich Tale
Aug 12, 2021
-
CNN
Biden struggles to find a permanent FDA chief as agency nears approval of Covid-19 vaccine
-
Science
'Landmark' study finds artificial antibodies can protect against malaria
-
STAT
Scientist Aubrey de Grey put on leave over sexual harassment allegations
-
Evaluate Vantage
Fate looks to justify its $9bn valuation
Aug 11, 2021
-
Endpoints News
'The consummate mentor': Bill Clinton, Jim Wilson and others reflect on Tachi Yamada's life and legacy
-
C&EN
Big ambitions for India's contract research firms
-
Reuters
Inovio focused on launching global COVID-19 vaccine trial next month - CEO
-
FiercePharma
How did big pharma perform in China in H2?
Aug 10, 2021
-
Axios
Democrats' high-stakes fight against the prescription drug industry
-
The Wall Street Journal
RNA Tech Firm GreenLight Biosciences to Go Public in $1.5 Billion SPAC Deal
-
The New York Times
Scientist Settled Federal Whistle-Blowing Complaint Over Covid Treatments
-
Reuters
Gilead to require U.S. workers receive COVID-19 vaccine
Aug 09, 2021
-
POLITICO
Obamacare architect floated for top FDA job
-
The Boston Globe
A group of doctors, medical students seeks to prohibit Boston’s hospital chiefs from working on corporate boards
-
Endpoints News
Philip Morris bags another biotech as bidding war with Carlyle over Vectura deal heats up
-
FiercePharma
AstraZeneca chief Soriot lends GlaxoSmithKline's Walmsley CEO wisdom, support as activist investors press for change
Aug 06, 2021
-
The Wall Street Journal
FDA Covid-19 Vaccine Booster Plan Could Be Ready Within Weeks
-
FierceBiotech
Dicerna drops after mixed data on rival to Alnylam drug
-
Science
A giant trial of COVID-19 treatments is restarting. Here are the drugs it’s betting on
-
Reuters
Gilead says aware of counterfeit HIV medicines being distributed in U.S.
Previous
